undamentalytics Newsletter
Sign in

The Cooper Companies (COO) stock

Add to watchlist

Add holding +

NASDAQ: COO Nasdaq Health Care Supplies Next results ~December 3, 2026

B Fundamentals grade

The Cooper Companies is a global medical device business headquartered in San Ramon, California, selling products in over 130 countries. It operates through two segments: CooperVision and CooperSurgical. CooperVision designs, manufactures and markets contact lenses, including the Biofinity, MyDay, Avaira Vitality and clariti brands, alongside myopia management lenses such as MiSight 1 day and other specialty lenses for astigmatism and presbyopia. CooperSurgical supplies medical devices and services for gynaecology, obstetrics and fertility, with over 600 products including surgical instruments, the Paragard copper IUD, cord blood and tissue cryostorage, and IVF-related media, tools and genomic testing services.

Customers include contact lens wearers, optical retailers and buying groups for CooperVision, and OB/GYN practices, hospitals, ambulatory surgery centres and fertility clinics for CooperSurgical, with some direct-to-consumer sales. Revenue comes from product sales rather than subscriptions or licensing, covering lenses, surgical devices, IUDs, and storage and laboratory services.

Manufacturing and distribution facilities span Belgium, Costa Rica, Hungary, Puerto Rico, the UK, the US and the Netherlands, among other locations. CooperSurgical, founded in 1990, has grown through product development and acquisitions. The company states its products reach over fifty million people annually, and it employs roughly 500 staff in research and development across both segments.

Based on The Cooper Companies's 10-K filed December 5, 2025.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

~$35

Cash-flow model

Base case. Range ~$23–$51 across our lower- and higher-growth cases (0.6%–10.6% a year).

Price vs value

Overvalued

The price is above our entire value range; our base value is 42% below it.

Price used: $61.30, November 2, 2026

The Cooper Companies valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

Value diary

Our note on each quarter The Cooper Companies files

Where Cooper Companies (The) stands after its latest 10-Q

Revenue for the twelve months to July 2026 was $4.24bn, up 4.7% on a year earlier, slower than 6.1% a quarter earlier. Free-cash-flow margin rose to 16.0% from 10.2% a year earlier. Operating margin narrowed to 12.8% from 18.3%. The diluted share count is down 2.4% on a year earlier, which lifts each remaining share. Against its peers on growth, profitability, cash generation and balance sheet, it grades C. It passes 5 of our 7 financial-health checks. Our cash-flow model value is $30.34 a share, against a share price of $58.83. At that price, our model says the market is pricing in about 15.4% a year of cash-flow growth for five years, faster than the 7.7% a year revenue growth it has delivered.

Source: 10-Q filed September 9, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~December 3, 2026 (estimated)

The Cooper Companies's trailing-twelve-month revenue grew 4.7% year on year, with a free-cash-flow margin of 16.0%. Where it stands out: net margin of 13.5% ranks 2 of 13 health care supplies companies we cover.

Our discounted-cash-flow model values the business at ~$35 per share in the base case (~$23–$51 across growth scenarios) — model values under stated assumptions, not a price target.

Current signal Free cash flow diverging from earnings: TTM free cash flow grew 64.6% while net income grew 39.8%: a 25pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Shrinking share count. Diluted shares fell 2.4% in a year, so each share owns more of the business.
  • Beating expectations. Earnings per share beat the analysts' consensus estimate in each of the last four quarters.

Things to watch

  • Priced above our value. The share price of $61.30 is 42% above our value per share of $35.
  • Margins narrowing. Operating margin is down 5.5 points on a year ago.
  • Estimates being cut. Analysts' consensus for next year's earnings per share has fallen 6.1% over 90 days.

Latest results: FY2026 Q3

Filed September 9, 2026
Earnings per share
$1.15 against an average estimate of $1.12: beat by 2.7%
Revenue
$1.07bn, up 0.6% on a year earlier
Share reaction
-20.0% in the first session after the results on September 9, 2026, against -1.1% for the S&P 500
Guidance given
total revenue $1.06bn to $1.08bn (fiscal fourth quarter 2026); organic growth growth 0% to 2% (fiscal fourth quarter 2026)
Next report
September 9, 2026; average EPS estimate $1.07

The Cooper Companies' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+2.9%
  • 1 week+0.3%
  • 1 month+7.7%
  • This year-25.2%
  • 1 year-12.3%
  • 5 years-41.9%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$4.2B
Operating margin
12.8%
Net margin
13.5%
EPS (TTM, diluted)
$2.91

Growth

Revenue growth
+4.7%
Change in growth rate
−1.4 pts
Share count change
−2.4%

Cash

Free cash flow (TTM)
$678M
FCF margin
16.0%
Stock pay % of revenue
1.6%

Earnings

Last results
September 9, 2026
Next results (est.)
December 3, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Leadership
  2. Results
  3. Guidance
  4. Announcement
  5. Announcement
  6. Announcement
  7. Announcement
  8. Announcement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

The Cooper Companies valuation models and calculator

What the price is pricing in

The share price implies about 12.6% a year of cash-flow growth for five years.That is close to the 7.7% a year revenue growth The Cooper Companies has delivered.

  • Priced in12.6%
  • Last 12 months4.7%
  • 3 years a year6.4%
  • 5 years a year7.7%

Our cash-flow model with every input fixed except growth over the next five years, solved for the growth at which the model value equals the share price ($60.45, Nov 3, 2026). Cash-flow growth then fades to 2.5% a year; discount rate 8.5%. Delivered figures are revenue growth from SEC filings. This is a model exercise, not investment advice or a forecast of the share price. All companies

Fundamentalytics rating

model v1.6 · 2026-11-03
Sell12-month view
12-month price target
~$35
Price used
$60.45close November 3, 2026
Implied change
▼ 42%
Uncertainty
Medium

How we got here: a discounted-cash-flow model of The Cooper Companies's free cash flow after stock-based pay with after-tax interest added back ($459M, FY2026 Q3 TTM), growing 3.7% and 5% in the next two years (forecasts, guidance and its record), then back to 5.6% by year five, and fading to 2.5%, discounted at 8.5%. Lower and higher growth cases span ~$23–~$51 ; that spread sets a 25% margin before we rate Buy or Sell.

Produced by Fundamentalytics' automated valuation model on November 3, 2026, using delayed market prices. Rating meanings, methodology and conflicts: recommendations disclosure and research disclaimer. General research, not personal advice — it does not consider your circumstances. Prices can fall as well as rise.

Our value per share comes from a discounted-cash-flow model of The Cooper Companies's free cash flow after stock-based pay ( $459M, FY2026 Q3 TTM, with after-tax interest added back): growth for five years as below (the first two years from forecasts, guidance and the company's record), fading to 2.5%, discounted at 8.5%, then cash added and debt and other claims subtracted. These are model values under stated assumptions, not price targets or recommendations.

Valuation models

We value The Cooper Companies as an operating company, with every model that fits that kind of business. Cost of equity 8.6%: the 10-year Treasury yield (4.9%) plus a beta of 0.81 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Cash-flow model (DCF) Free cash flow to the firm (after stock pay, with after-tax interest added back), grown then faded to 2.5%, discounted at 8.5% as the firm rate, less debt and other claims. ~$35 ~$23–$51 Primary model, counts double
Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$51 ~$52–$120 Included
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. ~$26 ~$16–$42 Included
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. ~$18 ~$15–$22 Included
Combined value Weighted average of the models that apply: the primary model (cash-flow model (dcf)) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$33 ~$18–$51 4 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare The Cooper Companies with Health Care Supplies in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

What moves the value

  • Revenue growth 5 points lower ▼ −30%
  • Revenue growth 5 points higher ▲ +39%
  • Free-cash-flow margin 1 point lower ▼ −7%
  • Last year's free-cash-flow margin change, if it persists ▲ +65%
  • Discount rate 1 point higher ▼ −17%
Value per share under different assumptions
Discount rate ↓ / growth → −5% growth0% growth5% growth10% growth15% growth20% growth
7% $22$35$51$73$101$138
8.5% $14$23$35$51$71$97
10% $9$16$25$37$53$72

Valuation multiples over time Market data may be delayed

At fiscal year end 2016201720182019202020212022202320242025Now
Share price$43.95$60.00$64.52$72.70$79.72$104.19$68.34$77.94$104.68$69.91$61.30
Market value$8.6bn$11.9bn$12.8bn$14.5bn$15.8bn$20.8bn$13.6bn$15.5bn$21.0bn$14.0bn$12.0bn
+ Net debt (− = net cash)$1.4bn$1.1bn$1.9bn$1.7bn$1.7bn$1.4bn$2.6bn$2.4bn$2.5bn$2.4bn$2.4bn
Enterprise value$10.1bn$13.0bn$14.8bn$16.3bn$17.5bn$22.1bn$16.2bn$18.0bn$23.5bn$16.4bn$14.4bn
Multiples
Price / sales 4.4x5.6x5.1x5.5x6.5x7.1x4.1x4.3x5.4x3.4x2.8x
Price / earnings 31.4x31.9x91.7x31.2x66.3x7.0x35.2x52.8x53.5x37.3x21.0x
Price / free cash flow 24.1x25.5x27.0x34.5x89.8x39.6x30.2x72.2x72.8x32.2x17.7x
EV / EBITDA 19.3x21.0x21.8x19.7x37.9x27.2x19.0x20.0x21.7x15.4x17.3x

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

73 /100

Strong moat

How hard The Cooper Companies's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 8 / 20

    Cash operating profit has been a median 7.0% of total assets over 10 years.

  • Pricing power 20 / 20

    Gross margin has been a median 65.7%, moving by 1.3 percentage points (standard deviation) across 10 years.

  • Durability 15 / 20

    Operating margin has been a median 16.7%; its worst year was 12.8%.

  • Cash conversion 18 / 20

    Free cash flow was positive in 10 of 10 years, at a median 16.1% of revenue.

  • Discipline 17 / 20

    The diluted share count fell 1.5% over five years; stock-based pay has been a median 1.6% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (78 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $4.53 +10% $4.2bn +4%
Next $4.69 +4% $4.4bn +4%

Next year's EPS estimate has moved −6.1% in 90 days, across 17 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −2.1% on 90 days ago. In the last 30 days, 0 analysts raised The Cooper Companies's forecast and 16 cut it.

Consensus EPS forecast The Cooper Companies, last 90 days
$4.40 $4.60 $4.80 $5.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: $4.63 Current fiscal year, 60 days ago: $4.63 Current fiscal year, 30 days ago: $4.53 Current fiscal year, 7 days ago: $4.53 Current fiscal year, Now: $4.53 $4.53 Next fiscal year, 90 days ago: $5.00 Next fiscal year, 60 days ago: $5.00 Next fiscal year, 30 days ago: $4.69 Next fiscal year, 7 days ago: $4.69 Next fiscal year, Now: $4.69 $4.69

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago $4.63$5.00
60 days ago $4.63$5.00
30 days ago $4.53$4.69
7 days ago $4.53$4.69
Now $4.53$4.69

Earnings against estimates

Quarter toEstimateActualSurprise
Jul 2026 $1.12 $1.15 +2.7%
Apr 2026 $1.09 $1.21 +10.5%
Jan 2026 $1.03 $1.10 +7.0%
Oct 2025 $1.11 $1.15 +3.3%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, September 9, 2026
  • total revenue fiscal 2026 $4.229bn to $4.252bn
    “Fiscal 2026 total revenue of $4.229 - $4.252 billion (organic growth of 2% to 3%)” source
  • total revenue fiscal fourth quarter 2026 $1.057bn to $1.08bn
    “Fiscal fourth quarter 2026 total revenue of $1.057 - $1.080 billion (organic growth of 0% to 2%)” source
  • non-GAAP diluted EPS fiscal 2026 $4.51 to $4.55 Non-GAAP
    “Fiscal 2026 non-GAAP diluted EPS of $4.51 - $4.55” source
  • non-GAAP diluted EPS fiscal fourth quarter 2026 $1.05 to $1.09 Non-GAAP
    “Fiscal fourth quarter 2026 non-GAAP diluted EPS of $1.05 -$1.09” source
  • organic growth fiscal 2026 2% growth to 3% growth
    “Fiscal 2026 total revenue of $4.229 - $4.252 billion (organic growth of 2% to 3%)” source
  • CVI revenue · CooperVision (CVI) fiscal 2026 $2.828bn to $2.842bn
    “CVI revenue of $2.828 - $2.842 billion (organic growth of 1% to 2%)” source
Show 9 more items
  • CVI organic growth · CooperVision (CVI) fiscal 2026 1% growth to 2% growth
    “CVI revenue of $2.828 - $2.842 billion (organic growth of 1% to 2%)” source
  • CSI revenue · CooperSurgical (CSI) fiscal 2026 $1.401bn to $1.41bn
    “CSI revenue of $1.401 - $1.410 billion (organic growth of 4% to 5%)” source
  • CSI organic growth · CooperSurgical (CSI) fiscal 2026 4% growth to 5% growth
    “CSI revenue of $1.401 - $1.410 billion (organic growth of 4% to 5%)” source
  • organic growth fiscal fourth quarter 2026 0% growth to 2% growth
    “Fiscal fourth quarter 2026 total revenue of $1.057 - $1.080 billion (organic growth of 0% to 2%)” source
  • CVI revenue · CooperVision (CVI) fiscal fourth quarter 2026 $692m to $706m
    “CVI revenue of $692 -$706 million (organic growth of -2% to 0%)” source
  • CVI organic growth · CooperVision (CVI) fiscal fourth quarter 2026 -2% growth to 0% growth
    “CVI revenue of $692 -$706 million (organic growth of -2% to 0%)” source
  • CSI revenue · CooperSurgical (CSI) fiscal fourth quarter 2026 $364m to $374m
    “CSI revenue of $364 - $374 million (organic growth of 4% to 6%)” source
  • CSI organic growth · CooperSurgical (CSI) fiscal fourth quarter 2026 4% growth to 6% growth
    “CSI revenue of $364 - $374 million (organic growth of 4% to 6%)” source
  • long-term free cash flow objective fiscal years 2026 through 2028 — Maintained
    “Reaffirm previously communicated long-term free cash flow objective exceeding $2.2 billion for fiscal years 2026 through 2028” source

Figures and quotations are management's, copied from the company's own press release (SEC 8-K exhibit) and checked word for word against it. Forward-looking statements are the company's expectations, not ours and not advice; guidance can change or be missed.

How our valuation uses these forecasts

Our cash-flow model grows The Cooper Companies's revenue by +3.7% next year and +5.0% the year after, then fades back toward its own record by year five. Next year's rate weighs analysts' consensus (+3.1%, weight 56%) , management guidance (+3.1%, weight 19%) and the company's own record (+5.6%, weight 25%) . How the weights are set.

Analyst recommendations

17 analysts, Oct 2026
Buy529%
Hold1271%
Sell00%

Monthly trend

  1. Oct 2026231217
  2. Sep 2026231116
  3. Aug 202646616
  4. Jul 202646616

Counts of recommendations published by analysts covering The Cooper Companies, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
5.5%
of tradable shares
Days to cover
2.03
at average volume
Short interest, 1 month
−9%
to October 15, 2026
Held by institutions
—
of shares
Held by insiders
0.6%
of shares
Employees
15,000
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months −12.3%

$69.91 on October 31, 2025 to $61.30

ThenNowEffect
Revenue (last 12 months) $4.0bn $4.2bn +4.7%
Net margin 10.1% 13.5% +33.5%
P/E multiple 34.4x 21.0x −38.8%
Share count 201m 196m +2.5%

Biggest factor: p/e multiple.

Last 3 years −26.7%

$83.66 on November 3, 2023 to $61.30

ThenNowEffect
Revenue (last 12 months) $3.5bn $4.2bn +20.6%
Net margin 7.8% 13.5% +71.8%
P/E multiple 60.5x 21.0x −65.2%
Share count 199m 196m +1.6%

Biggest factor: p/e multiple.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
COO+15%−21%+15%−3%−11%−25%
Industry peers (median)+17%−50%+38%−13%−20%−7%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
COO67%50%58%50%50%46%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
COO−18%−42%−23%−18%−35%−37%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 53% from September 3, 2021 to September 15, 2026. Getting back needed a 114% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$53.27 – $84.32
From 52-week high
−27.3%
vs 50-day average
+2.1%
vs 200-day average
−10.9%
Volatility (1 year)
32%
Beta vs S&P 500
0.45

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
5 up, 7 down
typical move ±9.3%
After a week
6 up, 6 down
typical move ±10.5%
After a month
5 up, 7 down
typical move ±12.5%
Results releasedNext dayS&P 500 next day5 days21 days
September 9, 2026 −20.0% −1.1% −19.3% −19.8%
June 4, 2026 +11.6% −2.2% +11.9% +19.1%
March 5, 2026 −6.6% −1.9% −12.8% −14.3%
December 4, 2025 +7.1% +0.3% +8.1% +11.0%
August 27, 2025 −12.3% +0.6% −7.7% −8.3%
May 29, 2025 −14.8% +0.3% −11.2% −11.2%
March 6, 2025 −6.9% −1.2% −14.9% −19.2%
December 5, 2024 −6.0% 0.0% −7.9% −11.7%
August 28, 2024 +12.1% −0.6% +12.9% +16.4%
May 30, 2024 +3.5% +0.2% +4.5% −5.2%
February 29, 2024 +8.1% +1.3% +8.0% +5.0%
December 7, 2023 −2.2% +1.2% +7.2% +8.4%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Options strategies

All options ideas

How The Cooper Companies’s listed options are priced, and three ways to use them that follow from our valuation. Quotes are delayed, read November 2, 2026. Check the live chain at your broker before trading.

Cash-secured put

Not offered: rated Sell.

We suggest selling a put only on well-rated companies, at a strike where the price you would pay if assigned (strike less premium) is at or below our fair value.

Covered call

Not offered: no liquid call at or above our price target — the model says the upside is worth more than any listed strike.

For holders: sell a call at a strike at or above our fair value, so the shares are only sold at a price the model calls full value.

Collar

Not offered: no liquid put and call pair for the same expiry.

For holders of a stock trading at or above our fair value: buy a put for a floor and sell a call to pay for it.

General research, not personal advice. Options can lose you more than you expect and are not suitable for everyone: put sellers can be made to buy shares that keep falling, call sellers give up gains above the strike, and results or news can move prices sharply. Chances shown are approximations from each option’s delta. Spreads, fees and early assignment are not modelled.

The Cooper Companies in five measures

Fundamentals grade B
Growth Profitability Cash Balance sheet Value

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) The Cooper Companies
$3.4B $3.6B $3.8B $4B $4.2B $4.4B FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Revenue (TTM), FY23 Q4: $3.6B Revenue (TTM), FY24 Q1: $3.7B Revenue (TTM), FY24 Q2: $3.7B Revenue (TTM), FY24 Q3: $3.8B Revenue (TTM), FY24 Q4: $3.9B Revenue (TTM), FY25 Q1: $3.9B Revenue (TTM), FY25 Q2: $4B Revenue (TTM), FY25 Q3: $4B Revenue (TTM), FY25 Q4: $4.1B Revenue (TTM), FY26 Q1: $4.2B Revenue (TTM), FY26 Q2: $4.2B Revenue (TTM), FY26 Q3: $4.2B $4.2B

Source: SEC EDGAR filings. Retrieved October 20, 2026.

View chart data
Period Revenue (TTM)
FY23 Q4 $3.6B
FY24 Q1 $3.7B
FY24 Q2 $3.7B
FY24 Q3 $3.8B
FY24 Q4 $3.9B
FY25 Q1 $3.9B
FY25 Q2 $4B
FY25 Q3 $4B
FY25 Q4 $4.1B
FY26 Q1 $4.2B
FY26 Q2 $4.2B
FY26 Q3 $4.2B
Revenue growth, TTM YoY The Cooper Companies
4% 6% 8% 10% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Revenue growth, TTM YoY, FY23 Q4: 8.6% Revenue growth, TTM YoY, FY24 Q1: 8.5% Revenue growth, TTM YoY, FY24 Q2: 8.9% Revenue growth, TTM YoY, FY24 Q3: 8.2% Revenue growth, TTM YoY, FY24 Q4: 8.4% Revenue growth, TTM YoY, FY25 Q1: 7.2% Revenue growth, TTM YoY, FY25 Q2: 6.9% Revenue growth, TTM YoY, FY25 Q3: 6.4% Revenue growth, TTM YoY, FY25 Q4: 5.1% Revenue growth, TTM YoY, FY26 Q1: 5.7% Revenue growth, TTM YoY, FY26 Q2: 6.1% Revenue growth, TTM YoY, FY26 Q3: 4.7% 4.7%

Source: SEC EDGAR filings. Retrieved October 20, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q4 8.6%
FY24 Q1 8.5%
FY24 Q2 8.9%
FY24 Q3 8.2%
FY24 Q4 8.4%
FY25 Q1 7.2%
FY25 Q2 6.9%
FY25 Q3 6.4%
FY25 Q4 5.1%
FY26 Q1 5.7%
FY26 Q2 6.1%
FY26 Q3 4.7%
Operating margin (TTM) The Cooper Companies
10% 12% 14% 16% 18% 20% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Operating margin (TTM), FY23 Q4: 14.8% Operating margin (TTM), FY24 Q1: 14.6% Operating margin (TTM), FY24 Q2: 16.1% Operating margin (TTM), FY24 Q3: 16.9% Operating margin (TTM), FY24 Q4: 18.1% Operating margin (TTM), FY25 Q1: 18.7% Operating margin (TTM), FY25 Q2: 19.0% Operating margin (TTM), FY25 Q3: 18.3% Operating margin (TTM), FY25 Q4: 16.7% Operating margin (TTM), FY26 Q1: 17.2% Operating margin (TTM), FY26 Q2: 11.8% Operating margin (TTM), FY26 Q3: 12.8% 12.8%

Source: SEC EDGAR filings. Retrieved October 20, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q4 14.8%
FY24 Q1 14.6%
FY24 Q2 16.1%
FY24 Q3 16.9%
FY24 Q4 18.1%
FY25 Q1 18.7%
FY25 Q2 19.0%
FY25 Q3 18.3%
FY25 Q4 16.7%
FY26 Q1 17.2%
FY26 Q2 11.8%
FY26 Q3 12.8%
FCF margin (TTM) The Cooper Companies
0% 5% 10% 15% 20% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 FCF margin (TTM), FY23 Q4: 6.0% FCF margin (TTM), FY24 Q1: 3.7% FCF margin (TTM), FY24 Q2: 3.3% FCF margin (TTM), FY24 Q3: 5.0% FCF margin (TTM), FY24 Q4: 7.4% FCF margin (TTM), FY25 Q1: 9.8% FCF margin (TTM), FY25 Q2: 9.2% FCF margin (TTM), FY25 Q3: 10.2% FCF margin (TTM), FY25 Q4: 10.6% FCF margin (TTM), FY26 Q1: 11.8% FCF margin (TTM), FY26 Q2: 13.5% FCF margin (TTM), FY26 Q3: 16.0% 16.0%

Source: SEC EDGAR filings. Retrieved October 20, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q4 6.0%
FY24 Q1 3.7%
FY24 Q2 3.3%
FY24 Q3 5.0%
FY24 Q4 7.4%
FY25 Q1 9.8%
FY25 Q2 9.2%
FY25 Q3 10.2%
FY25 Q4 10.6%
FY26 Q1 11.8%
FY26 Q2 13.5%
FY26 Q3 16.0%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Where the money goes

FY2025, from the 10-K

Each dollar The Cooper Companies took in during FY2025, followed through to profit: what it cost to make, what went on research and running the business, and what was left after tax.

  1. Revenue $4.1B
  2. Cost of revenue $1.4B · 34.5%
  3. Gross profit $2.7B · 65.5%
  4. Research and development $172M · 4.2%
  5. Selling, general and admin $1.6B · 39.8%
  6. Other operating costs $199M · 4.9%
  7. Operating income $683M · 16.7%
  8. Income tax $192M · 4.7%
  9. Interest and other $116M · 2.8%
  10. Net income $375M · 9.2%

Shares of revenue. Source: The Cooper Companies's 10-K for FY2025, as filed with the SEC. "Other" lines are what the reported lines leave unexplained.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2009 Oct 2009 2010 Oct 2010 2011 Oct 2011 2012 Oct 2012 2013 Oct 2013 2014 Oct 2014 2015 Oct 2015 2016 Oct 2016 2017 Oct 2017 2018 Oct 2018 2019 Oct 2019 2020 Oct 2020 2021 Oct 2021 2022 Oct 2022 2023 Oct 2023 2024 Oct 2024 2025 Oct 2025 LTM Jul 2026
Income
Revenue 1,080 1,159 1,331 1,445 1,588 1,718 1,797 1,967 2,139 2,533 2,653 2,431 2,923 3,308 3,593 3,895 4,092 4,237
Gross profit 596 677 805 924 1,027 1,092 1,070 1,173 1,366 1,632 1,757 1,535 1,956 2,140 2,358 2,596 2,682 2,793
EBITDA 242 284 326 395 431 445 428 522 618 678 828 462 815 854 901 1,081 1,060 834
Operating income 150 190 228 283 306 306 237 324 429 403 547 312 506 508 533 706 683 544
Net income 101 113 175 248 296 270 204 274 373 140 467 238 2,945 386 294 392 375 570
Diluted EPS $0.55 $0.61 $0.91 $1.26 $1.49 $1.38 $1.03 $1.40 $1.88 $0.70 $2.33 $1.20 $14.79 $1.94 $1.48 $1.96 $1.87 $2.91
Growth (year on year)
Revenue +3.2% +7.2% +14.9% +8.6% +9.9% +8.2% +4.6% +9.4% +8.8% +18.4% +4.8% −8.4% +20.2% +13.2% +8.6% +8.4% +5.1% +4.7%
EBITDA +15.9% +17.1% +14.7% +21.2% +9.3% +3.1% −3.7% +22.0% +18.2% +9.8% +22.0% −44.2% +76.5% +4.7% +5.5% +20.0% −1.9% −17.6%
Operating income +18.0% +26.7% +19.8% +24.5% +8.0% +0.2% −22.8% +36.9% +32.4% −6.1% +35.6% −43.0% +62.2% +0.4% +5.0% +32.4% −3.2% −26.5%
Net income +57.2% +12.2% +55.5% +41.6% +19.3% −8.9% −24.6% +34.6% +36.1% −62.5% +233.6% −48.9% +>999% −86.9% −23.7% +33.3% −4.4% +39.8%
Diluted EPS +55.6% +10.0% +49.4% +39.1% +18.0% −7.6% −24.9% +35.0% +34.5% −62.6% +232.0% −48.4% +>999% −86.9% −23.7% +32.4% −4.6% +43.3%
Margins
Gross margin 55.2% 58.4% 60.5% 63.9% 64.7% 63.5% 59.6% 59.6% 63.9% 64.4% 66.2% 63.1% 66.9% 64.7% 65.6% 66.6% 65.5% 65.9%
EBITDA margin 22.4% 24.5% 24.5% 27.3% 27.2% 25.9% 23.8% 26.6% 28.9% 26.8% 31.2% 19.0% 27.9% 25.8% 25.1% 27.7% 25.9% 19.7%
Operating margin 13.9% 16.4% 17.1% 19.6% 19.3% 17.8% 13.2% 16.5% 20.1% 15.9% 20.6% 12.8% 17.3% 15.3% 14.8% 18.1% 16.7% 12.8%
Net margin 9.3% 9.7% 13.2% 17.2% 18.7% 15.7% 11.3% 13.9% 17.4% 5.5% 17.6% 9.8% 100.8% 11.7% 8.2% 10.1% 9.2% 13.5%
Free-cash-flow margin 12.0% 16.7% 17.5% 14.9% 15.0% 12.6% 8.2% 18.2% 21.8% 18.8% 15.9% 7.2% 17.9% 13.6% 6.0% 7.4% 10.6% 16.0%
Cash flow
Cash from operations 223 268 336 315 416 455 391 510 594 669 713 487 739 692 608 709 796 1,033
Capital spending 94 74 104 100 178 238 243 153 127 194 292 310 214 242 393 421 362 355
Free cash flow 129 194 233 215 238 217 148 357 466 475 421 176 524 450 215 288 434 678
Stock-based pay 12 10 14 22 29 37 33 30 37 43 35 38 44 54 62 75 71 66
Free cash flow after stock pay 117 184 219 194 209 180 115 327 429 432 386 139 480 396 153 213 363 612
Balance sheet
Cash 4 4 5 13 77 25 16 101 89 78 89 116 96 138 121 108 111 155
Total debt 781 611 393 374 345 1,382 1,353 1,548 1,173 2,023 1,826 1,793 1,481 2,763 2,569 2,584 2,505 2,544
Net debt (negative = net cash) 778 608 388 361 267 1,357 1,337 1,447 1,084 1,945 1,737 1,677 1,385 2,625 2,448 2,476 2,395 2,390
Diluted shares 182m 186m 193m 197m 199m 196m 197m 196m 198m 199m 200m 198m 199m 199m 199m 200m 200m 196m
Returned to shareholders
Dividends 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 0 0 —
Buybacks — 0 0 71 167 76 67 0 55 0 156 48 25 79 0 0 290 644
Total returned 3 3 3 74 170 79 70 3 58 3 159 51 28 82 3 0 290 644

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

5 of 7 checks passed · July 31, 2026
What it owns · $12.7bn
Short-term assets $2.3bnLonger-term assets $10.4bn
What it owes, and who funded it · $12.7bn
Short-term liabilities $1.9bnLonger-term liabilities $2.5bnShareholders' equity $8.3bn
  • Short-term assets cover short-term liabilities $2.3bn of assets due within a year against $1.9bn of liabilities due within a year.
  • Short-term assets cover long-term liabilities $2.3bn short-term assets against $2.5bn of longer-dated liabilities.
  • More cash than debt $155m of cash against $2.5bn of debt.
  • Debt below 40% of shareholders' equity Debt is 31% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 34% to 31% over five years.
  • A year's operating cash flow covers at least 20% of debt $1.0bn of operating cash flow against $2.5bn of debt.
  • Operating profit covers interest at least five times over Operating income of $544m against $89m of interest.

From The Cooper Companies's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

FY2026 Q3 TTM
Buybacks (TTM)
$644M
Returned to shareholders
95%
of free cash flow
Buybacks, last 3 fiscal years
$290M
Diluted share count
−2.4%
year over year
Total shareholder yield
5.5%
dividends 0.0% + buybacks 5.5% of market value
R&D spending
4.0%
of revenue
Sales & admin spending
44.5%
of revenue
Days sales outstanding
68 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in health care supplies
Last 12 months unless stated COO ALGN XRAY WST NVST ICUI Median
Revenue, last 12 months $4.2bn $4.1bn $3.6bn $3.4bn $2.9bn $2.2bn $1.0bn
Revenue growth, last 12 months 4.7% 4.4% −0.8% 12.6% 11.9% −9.0% 3.4%
Revenue growth, 3-year average 6.4% 3.5% −2.5% 5.1% 3.4% −2.0% 0.0%
Revenue growth, latest quarter 0.6% 4.3% −4.1% 8.7% 7.1% 0.5% 0.6%
Gross margin 65.9% 68.0% 49.5% 37.6% 55.2% 39.1% 52.9%
Operating margin 12.8% 13.2% −8.5% 23.0% 9.6% 3.3% 3.3%
Operating margin, 3-year average 16.0% 14.9% −12.9% 20.8% −10.9% 2.2% 2.2%
Net margin 13.5% 10.0% −15.0% 18.8% 3.3% 1.4% 1.4%
Cash from operations / revenue 24.4% 18.3% 8.8% 19.3% 10.6% 10.9% 10.6%
Free-cash-flow margin 16.0% 15.3% 3.9% 13.3% 8.7% 6.7% 6.7%
Free-cash-flow margin, 3-year average 10.4% 13.8% 5.7% 12.4% 10.0% 5.2% 9.8%
Stock pay / revenue 1.6% 4.3% 0.9% 0.8% 1.4% 2.5% 2.5%
Change in share count −2.4% −2.8% 0.1% −1.5% −3.3% 2.5% −0.4%

Median of all 13 companies we cover in health care supplies. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

13 health care supplies companies
Measure Company Peer median Rank
Revenue growth Growth 4.7% 3.4% 5 of 13
Change in growth rate Growth -1.4pp -0.3pp 8 of 13
Gross margin Profitability 65.9% 52.9% 4 of 13
Operating margin Profitability 12.8% 3.3% 5 of 13
Net margin Profitability 13.5% 1.4% 2 of 13
Free-cash-flow margin Cash generation 16.0% 6.7% 2 of 13
Stock pay as % of revenue Cash generation 1.6% 2.5% 4 of 13
Long-term debt as % of assets Balance sheet 15.1% 15.4% 4 of 9
Change in share count Balance sheet -2.4% 0.1% 4 of 12
Days sales outstanding Balance sheet 68 days 65 days 7 of 11

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to October 31, 2025
Geography
Region Revenue Share YoY
United States $2.1B 50.2% ▲ 4.5%
Europe $1.3B 30.6% ▲ 8.4%
Rest of The World $785M 19.2% ▲ 1.5%

From The Cooper Companies's 10-K filed December 5, 2025, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$15B
Institutions reporting
667
Shares held vs prior quarter
▲ 2.4%
Positions opened / closed
104 / 100

Top buyers and sellers, Q2 2026: 358 institutions bought and 337 sold ; the biggest buyer was Citadel Advisors LLC (+3.7M shares) and the biggest seller Capital World Investors (−6.8M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $1.1B 15.0M 7.2% ▼ 9.6%
Vanguard Capital Management LLC $915M 12.8M 6.1% ▲ 0.3%
State Street Corp $638M 8.9M 4.2% ▲ 1.4%
Vanguard Portfolio Management LLC $622M 8.7M 4.1% ▼ 0.6%
T. Rowe Price Investment Management, Inc. $533M 7.4M 3.5% ▼ 18.0%
Browning West LP $516M 7.2M 3.4% ▲ 3.1%
Price T Rowe Associates Inc $400M 5.6M 2.7% ▲ 3.4%
Kayne Anderson Rudnick Investment Management LLC $389M 5.4M 2.6% ▼ 17.9%
Geode Capital Management, LLC $383M 5.4M 2.5% ▲ 0.9%
Franklin Resources Inc $365M 5.1M 2.4% ▲ 4.7%
Generation Investment Management LLP $356M 5.0M 2.4% ▲ 8.0%
Jupiter Topco LLC $305M 4.3M 2.0% —

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not The Cooper Companies's complete shareholder register. Values are as reported by the filers ; 1 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $3.2M 10 trades by 7 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $3.2M net buying
Insider Date Trade Shares Price Value
Kurzius Lawrence Erik Director September 16, 2026 Buy 10,000 $54.93 $549,320
Kurzius Lawrence Erik Director September 14, 2026 Buy 10,000 $53.91 $539,150
Rosebrough Walter M Jr Director September 14, 2026 Buy 3,000 $54.29 $162,870
Keel Paul A Director September 11, 2026 Buy 4,701 $53.18 $250,000
Rosebrough Walter M Jr Director September 11, 2026 Buy 7,000 $54.11 $378,770
Lucchese Cynthia L Director December 22, 2025 Buy 1,784 $84.06 $149,963
Rivas Maria Director December 18, 2025 Buy 1,000 $82.13 $82,130
Kurzius Lawrence Erik Director December 17, 2025 Buy 2,000 $82.50 $165,000
White Albert G Iii President & CEO December 16, 2025 Buy 10,000 $80.80 $808,000
Sheffield Holly R President, CSI December 16, 2025 Buy 1,230 $80.75 $99,322

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Trades by members of Congress

All 13 trades and filings

In the last 12 months, 1 member of Congress disclosed 3 purchases and 0 sales of The Cooper Companies shares.

  • Gilbert Ray Cisneros, Jr.(D-CA 31):Purchase, $1,001 - $15,000, traded June 5, 2026, filed July 2, 2026
  • Gilbert Ray Cisneros, Jr.(D-CA 31):Purchase, $1,001 - $15,000, traded May 29, 2026, filed June 8, 2026
  • Gilbert Ray Cisneros, Jr.(D-CA 31):Purchase, $1,001 - $15,000, traded December 10, 2025, filed January 12, 2026

Value ranges as filed; reports can arrive up to 45 days after a trade.

Earnings dates and SEC filings

Results announcements

Next expected around December 3, 2026 estimated from the company's past filing pattern, not announced

  • September 9, 2026
  • June 4, 2026
  • March 5, 2026
  • December 4, 2025
  • August 27, 2025
  • May 29, 2025

Recent SEC filings

Data status

When each part of this page on The Cooper Companies was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

The Cooper Companies in brief

What does The Cooper Companies do?
The Cooper Companies is a US-listed company in the health care supplies industry. Its financial year ends in October.
What is The Cooper Companies's stock ticker?
The Cooper Companies trades under the ticker COO on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is The Cooper Companies's revenue, and how fast is it growing?
Over its most recent trailing twelve months, The Cooper Companies reported revenue of $4.2B, 4.7% higher than a year earlier, according to its SEC filings.
What is The Cooper Companies's free cash flow?
The Cooper Companies's free-cash-flow margin is 16.0% of revenue over the trailing twelve months, ranking 2 of the 13 health care supplies companies we cover.
What is The Cooper Companies's fair value (intrinsic value) per share?
Our discounted-cash-flow model of The Cooper Companies's free cash flow after stock-based pay gives ~$35 per share in the base case, and ~$23–$51 across growth scenarios. These are model values under stated assumptions — not a price target or a recommendation.
Who are The Cooper Companies's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., Vanguard Capital Management LLC and State Street Corp. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Is The Cooper Companies buying back stock, and does it pay a dividend?
The Cooper Companies spent $644M on share repurchases over the trailing twelve months, and its diluted share count fell 2.4% over the year.
What is The Cooper Companies's market cap?
On November 2, 2026, The Cooper Companies's market capitalisation was about $12B, with a price-to-earnings ratio of 21.0 and net debt of $2.4B. Market figures come from third-party market data and may be delayed.
How much debt does The Cooper Companies have?
The Cooper Companies's debt-to-equity ratio is 30.5%, from its latest balance sheet (33.9% five years earlier). The financial health section below sets out its other solvency checks.
Who are The Cooper Companies's competitors?
In our Health Care Supplies peer group, the companies closest to The Cooper Companies are Align Technology, Dentsply Sirona Inc., West Pharmaceutical Services, Envista Holdings Corp and ICU Medical Inc. The side-by-side comparison below sets their revenue, margins and growth against The Cooper Companies's.
Are insiders buying or selling The Cooper Companies stock?
Over the last 12 months, The Cooper Companies's directors and officers reported 10 open-market purchases and 0 sales on Form 4. The insider trading page charts every trade.
When is The Cooper Companies's next earnings date?
Around December 3, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — The Cooper Companies announces its own schedule.